Personalized Cancer Therapy 


Scientific, Clinical, and Regulatory Advisors

Metaclipse has recruited several prominent scientists and clinicians to help define and guide its product development strategy.

William C. Wood, MD.  Dr. Wood is recognized nationally and internationally for his outstanding contributions to cancer therapy and his influence on the design and meta-analysis of conceptually driven national clinical trials. He served as both medical director of the Cancer Center and chief of surgical oncology at Massachusetts General Hospital before coming to Emory in 1991 to chair the Department of Surgery. The department has become noted for excellence in clinical care, education, and research.  He has extensively contributed to cancer therapy—most specifically breast cancer treatment—and influenced on the design and meta-analysis of conceptually driven national clinical trials. In his career he contributed to breast cancer treatment in the following: Chairing the Intergroup Committee of Cooperative Group Breast Cancer Chairs of the NCI from 1991-2008; co-chairing the Early Breast Cancer Trialists' Collaborative Group, Oxford, 1995-2011; sitting on the Board of Governors of the American College of Surgeons, 1998-2005; serving as Editor-in-Chief of Oncology, 1999-the present; being the North American editor of the 2nd edition of the Oxford Textbook of Surgery, published in 2000; receiving the 2005 James Ewing Award of the Society of Surgical Oncology and the 2007 Statesman Award of the American Society of Clinical Oncology; and serving presidential terms for the Southern Surgical Association, Society of Surgical Oncology, Southeastern Surgical Congress, Georgia Surgical Society, and the Atlanta Surgical Society. Dr. Wood stepped down from the Chairmanship of Surgery in February 2009 to intensify his focus on scholarly activities related to innovation in cancer treatment.

Rafi Ahmed, PhD.  Dr. Rafi Ahmed is the Director Emory Vaccine Research Center and renowned expert in T cell memory.  Dr. Ahmed holds the title of Georgia Research Alliance Scholar in Vaccine Research and is a Professor of Microbiology and Immunology in the Emory University School of Medicine. He received his Ph.D. in microbiology from Harvard University. Recently, he was elected as a member of the National Academy of Sciences of the United States.  Dr. Ahmed studies immunological memory – the ability of the immune system to “remember” a particular antigen and respond accordingly. Dr. Ahmed and his colleagues have made significant discoveries on how immune memory cells are created and survive; understanding these mechanisms is crucial to the development of vaccines for HIV and other infectious agents. His pioneering study demonstrated that exhausted T cells in chronic viral infections could be rescued by anti-PD1 antibody therapy. In addition to contributing vitally to vaccine science, Dr. Ahmed’s findings are being applied to research into therapies for the treatment of cancer and the prevention of organ rejection.

Harriet L. Robinson, PhD. Dr. Robinson is the developer of GeoVax's HIV-1 AIDS vaccine technology. One of the world's leaders in AIDS vaccine research, she currently serves as Chief Scientific Officer for GeoVax. Previously, she was Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center and the Candler Professor of Microbiology and Immunology at Emory University. Dr. Robinson has published extensively on HIV-AIDS vaccine research as well as viral-induced cancers. Her pioneering studies on the development of DNA vaccines demonstrated not only that DNA could raise protective immunity for viral infections, but also identified methods of DNA delivery that could be used to control the type of immune responses raised by DNA vaccines.. 

Jacques Galipeau, MD, FRCP(C). Dr. Galipeau is a world-renowned expert in cell and gene therapy of cancer and immune ailments. Most recently, Dr. Galipeau led a multidisciplinary team of researchers in developing a breakthrough experimental treatment that put multiple sclerosis into remission in mice by suppressing the immune system. Dr. Galipeau is a Professor of Hematology and Medical Oncology, Pediatrics and Medicine, Emory University School of Medicine.  He serves as Co-Director, Emory-Georgia Tech Center for Regenerative Therapy and Director, Emory-Georgia Tech Cell Therapy Facility.

Scott Burger, MD. Dr. Burger is the principal of Advanced Cell & Gene Therapy, a consulting firm specializing in cell, gene, and tissue-based therapies. Dr. Burger works with clients in industry and academic centers worldwide, providing assistance in process development and validation, GMP/GTP manufacturing, GMP facility design and operation, regulatory affairs, technology evaluation, and strategic analysis. He received his MD from the University of Pennsylvania, School of Medicine. He was medical director of the Cell Therapy Clinical Laboratory and Molecular and Cellular Therapeutics Facility at the University of Minnesota, responsible for process development, validation, and GMP production of a broad range of novel cell and gene therapies, in support of over 75 clinical trials. Dr. Burger was VP of Research and Development at Merix Bioscience involved in dendritic cell immunotherapy.

Rajesh Gupta, PhD. Dr. Gupta is the principal consultant at Biologics Quality and Regulatory Consultants, LLC. He has over 30 years in regulatory and quality experience in industry, including time at the Center for Biologics Evaluation and Research (CBER) at the FDA.  He is an expert in compliance with extensive experience and knowledge in development, manufacturing, and regulation of biological products.